Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.

Studied

Randomized comparison of semaglutide with placebo for long-term weight management, with behavioral intervention in both groups.

Who / model

304 adults with obesity, or overweight with a weight-related condition, without diabetes; studied for 104 weeks. Most participants were women and White.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Both primary outcomes favored semaglutide: average weight fell 15.2% versus 2.6%, and 77.1% versus 34.4% lost at least 5%. Digestive adverse events occurred in 82.2% versus 53.9%, mostly mild or moderate.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary